Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review

被引:542
作者
Hadinoto, Kunn [1 ]
Sundaresan, Ajitha [1 ]
Cheow, Wean Sin [1 ]
机构
[1] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 637459, Singapore
关键词
Hybrid nanoparticles; Lipid polymer; Liposomes; Core shell nanoparticles; Drug delivery; Gene delivery; COATED PLGA NANOPARTICLES; CORE-SHELL NANOPARTICLES; DRUG-DELIVERY; IN-VITRO; GENE DELIVERY; TARGETED NANOPARTICLES; SYSTEMIC DELIVERY; TUMOR; LIPOSOMES; RELEASE;
D O I
10.1016/j.ejpb.2013.07.002
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Lipid-polymer hybrid nanoparticles (LPNs) are core-shell nanoparticle structures comprising polymer cores and lipid/lipid-PEG shells, which exhibit complementary characteristics of both polymeric nanoparticles and liposomes, particularly in terms of their physical stability and biocompatibility. Significantly, the LPNs have recently been demonstrated to exhibit superior in vivo cellular delivery efficacy compared to that obtained from polymeric nanoparticles and liposomes. Since their inception, the LPNs have advanced significantly in terms of their preparation strategy and scope of applications. Their preparation strategy has undergone a shift from the conceptually simple two-step method, involving preformed polymeric nanoparticles and lipid vesicles, to the more principally complex, yet easier to perform, one-step method, relying on simultaneous self-assembly of the lipid and polymer, which has resulted in better products and higher production throughput. The scope of LPNs' applications has also been extended beyond single drug delivery for anticancer therapy, to include combinatorial and active targeted drug deliveries, and deliveries of genetic materials, vaccines, and diagnostic imaging agents. This review details the current state of development for the LPNs preparation and applications from which we identify future research works needed to bring the LPNs closer to its clinical realization. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:427 / 443
页数:17
相关论文
共 97 条
[1]
Nonviral Gene Delivery: Principle, Limitations, and Recent Progress [J].
Al-Dosari, Mohammed S. ;
Gao, Xiang .
AAPS JOURNAL, 2009, 11 (04) :671-681
[2]
Albanese A, 2012, ANNU REV BIOMED ENG, V14, P1, DOI [10.1146/annurev-bioeng-071811-150124, 10.1146/annurev.bioeng-071811-150124]
[3]
Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[4]
Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression [J].
Ambegia, E ;
Ansell, S ;
Cullis, P ;
Heyes, J ;
Palmer, L ;
MacLachlan, I .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2005, 1669 (02) :155-163
[5]
Nanoparticle drug delivery enhances the cytotoxicity of hydrophobic-hydrophilic drug conjugates [J].
Aryal, Santosh ;
Hu, Che-Ming Jack ;
Fu, Victoria ;
Zhang, Liangfang .
JOURNAL OF MATERIALS CHEMISTRY, 2012, 22 (03) :994-999
[6]
Polymeric Nanoparticles with Precise Ratiometric Control over Drug Loading for Combination Therapy [J].
Aryal, Santosh ;
Hu, Che-Ming Jack ;
Zhang, Liangfang .
MOLECULAR PHARMACEUTICS, 2011, 8 (04) :1401-1407
[7]
Combinatorial Drug Conjugation Enables Nanoparticle Dual-Drug Delivery [J].
Aryal, Santosh ;
Hu, Che-Ming Jack ;
Zhang, Liangfang .
SMALL, 2010, 6 (13) :1442-1448
[8]
Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method [J].
Barichello, JM ;
Morishita, M ;
Takayama, K ;
Nagai, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (04) :471-476
[9]
Polymer-supported lipid shells, onions, and flowers [J].
Bershteyn, Anna ;
Chaparro, Jose ;
Yau, Richard ;
Kim, Mikyung ;
Reinherz, Ellis ;
Ferreira-Moita, Luis ;
Irvine, Darrell J. .
SOFT MATTER, 2008, 4 (09) :1787-1791
[10]
Chan JM, 2010, P NATL ACAD SCI